Desiree Bonci

List of Publications by Year
in descending order

39 papers	5,890 citations	236925 25 h-index	330143 37 g-index
40 all docs	40 docs citations	40 times ranked	9000 citing authors

#	Article	IF	Citations
1	Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer. Cell Death and Disease, 2021, 12, 636.	6.3	20
2	Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases. Cell Death and Disease, 2019, 10, 201.	6.3	105
3	Renal cancer: new models and approach for personalizing therapy. Journal of Experimental and Clinical Cancer Research, 2018, 37, 217.	8.6	17
4	The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation. International Journal of Molecular Sciences, 2018, 19, 1183.	4.1	30
5	C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition. Oncogene, 2017, 36, 3718-3728.	5.9	35
6	miR-15/miR-16 loss, miR-21 upregulation, or deregulation of their target genes predicts poor prognosis in prostate cancer patients. Molecular and Cellular Oncology, 2016, 3, e1109744.	0.7	14
7	A microRNA code for prostate cancer metastasis. Oncogene, 2016, 35, 1180-1192.	5.9	115
8	Abstract LB-040: Establishment of a predictive patient-derived xenograft model for renal cell carcinoma. , 2016, , .		0
9	A predictive signature for therapy assignment and risk assessment in prostate cancer. Oncoscience, 2015, 2, 920-923.	2.2	5
10	MicroRNA as New Tools for Prostate Cancer Risk Assessment and Therapeutic Intervention: Results from Clinical Data Set and Patientsâ€™ Samples. BioMed Research International, 2014, 2014, 1-17.	1.9	46
11	BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelialâ€“mesenchymal transition. Oncogene, 2013, 32, 1843-1853.	5.9	94
12	A tight junction between E-Cadherin and the prostate tumor suppressor SPDEF. Asian Journal of Andrology, 2013, 15, 449-450.	1.6	1
13	Functional Role of MicroRNAs in Prostate Cancer and Therapeutic Opportunities. Critical Reviews in Oncogenesis, 2013, 18, 303-316.	0.4	5
14	MicroRNAs and Prostate Cancer. Cancer Journal (Sudbury, Mass), 2012, 18, 253-261.	2.0	35
15	Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia. Genes and Immunity, 2012, 13, 109-119.	4.1	70
16	Deregulation of microRNA-503 Contributes to Diabetes Mellitusâ€“Induced Impairment of Endothelial Function and Reparative Angiogenesis After Limb Ischemia. Circulation, 2011, 123, 282-291.	1.6	374
17	Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene, 2011, 30, 4231-4242.	5.9	221
18	MicroRNAs and prostate cancer. Endocrine-Related Cancer, 2010, 17, F1-F17.	3.1	139

#	Article	IF	Citations
19	Manipulating the Cell Differentiation Through Lentiviral Vectors. Methods in Molecular Biology, 2010, 614, 149-160.	0.9	3
20	MicroRNA-21 as Therapeutic Target in Cancer and Cardiovascular Disease. Recent Patents on Cardiovascular Drug Discovery, 2010, 5, 156-161.	1.5	47
21	Abstract 4045: Restoring miR-15a/16 in the NZB mouse model of chronic lymphocytic leukemia reduces disease and enhances drug sensitivity. , 2010, , .		0
22	Akt regulates L-type Ca2+ channel activity by modulating CavÎ±1 protein stability. Journal of Cell Biology, 2009, 184, 923-933.	5.2	101
23	THE MIR-15A/MIR-16-1 CLUSTER CONTROLS PROSTATE CANCER PROGRESSION CONTROL BY TARGETING OF MULTIPLE ONCOGENIC ACTIVITIES. Journal of Urology, 2009, 181, 188-188.	0.4	3
24	Green fluorescent protein incorporation by mouse myoblasts may yield false evidence of myogenic differentiation of human haematopoietic stem cells. Acta Physiologica, 2008, 193, 249-256.	3.8	2
25	The miR-15aâ€“miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nature Medicine, 2008, 14, 1271-1277.	30.7	919
26	A lentiviral vector with a short troponin-I promoter for tracking cardiomyocyte differentiation of human embryonic stem cells. Gene Therapy, 2008, 15, 161-170.	4.5	35
27	Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity. Haematologica, 2008, 93, 1899-1902.	3.5	7
28	The Inhibition of the Highly Expressed Mir-221 and Mir-222 Impairs the Growth of Prostate Carcinoma Xenografts in Mice. PLoS ONE, 2008, 3, e4029.	2.5	219
29	MicroRNA-133 controls cardiac hypertrophy. Nature Medicine, 2007, 13, 613-618.	30.7	1,652
30	Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line. Cell Death and Differentiation, 2006, 13, 61-74.	11.2	24
31	Lentiviral Transduction of Human Postnatal Skeletal (Stromal, Mesenchymal) Stem Cells: In Vivo Transplantation and Gene Silencing. Calcified Tissue International, 2006, 78, 372-384.	3.1	29
32	MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18081-18086.	7.1	747
33	Absence of Caspase 8 and High Expression of PED Protect Primitive Neural Cells from Cell Death. Journal of Experimental Medicine, 2004, 200, 1257-1266.	8.5	101
34	Heart infarct in NODâ€SCID mice: Therapeutic vasculogenesis by transplantation of human CD34 + cells and low dose CD34 + KDR + cells. FASEB Journal, 2004, 18, 1392-1394.	0.5	107
35	Potential role of APRIL as autocrine growth factor for megakaryocytopoiesis. Blood, 2004, 104, 3169-3172.	1.4	27
36	â€˜Advancedâ€™ generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Therapy, 2003, 10, 630-636.	4.5	109

#	Article	IF	Citations
37	Cardiomyocytes. , 2003, 229, 169-179.		1
38	Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature, 1999, 401, 489-493.	27.8	369
39	Formation of PML/RARÎ± high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RARÎ±-mediated retinoic acid response. Oncogene, 1999, 18, 6313-6321.	5.9	40